Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
OraSure Technologies (OSUR) Tops Q2 EPS by 2c
August 5, 2015 5:47 PM EDTOraSure Technologies (NASDAQ: OSUR) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $30.4 million versus the consensus estimate of $28.95 million.
"We are pleased with the record level of revenues reported for the second... More
OraSure Technologies (OSUR) Announces Receipt of FDA Emergency Use Authorization for OraQuick Ebola Test
August 3, 2015 6:48 AM EDTOraSure Technologies (NASDAQ: OSUR) announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick Ebola Rapid Antigen Test for use with fingerstick and venous whole blood.
This test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories and facilities adequately equipped, trained, and capable of testing for Ebola infection (including treatment centers and public health clinics).
The OraQuick® Ebola Rapid Antigen Test utilizes the OraQuick technology platform... More
